The biochemical inhibition mechanisms of p49/STRAP inhibitors are multifaceted, targeting various signaling pathways to achieve a decrease in the protein's functional activity. Inhibitors that target kinase activity are particularly effective, as they directly interfere with the kinase signaling cascades that p49/STRAP is known to interact with. For instance, the inhibition of broad kinase activities can prevent the phosphorylation and activation of serine/threonine kinases, which are crucial for the optimalfunctioning of p49/STRAP. Phosphoinositide 3-kinase inhibitors disrupt key signaling pathways such as PI3K/AKT/mTOR, leading to a reduction in the activity of proteins that are regulated by phosphorylation events within this network. Additionally, by specifically targeting pivotal kinases like mTOR, MEK1/2, and p38 MAPK, the inhibitors can further modulate the kinase-dependent signaling processes. This regulatory effect on kinase activity can lead to a downstream decrease in p49/STRAP activity due to the protein's reliance on proper kinase function and signaling for its role in the cell.
Moreover, the indirect inhibition approach extends to targeting stress-activated protein kinases and the MAPK/ERK pathway, both of which are vital for certain cellular responses and may interact with serine/threonine kinase signaling. Inhibitors of these pathways, such as those affecting JNK or preventing the activation of ERK, can alter the cellular signaling environment in which p49/STRAP operates, resulting in its functional inhibition. The strategic inhibition of these signaling pathways ensures that the activity of p49/STRAP is curtailed by influencing the phosphorylation states and interactions that are essential for its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases. p49/STRAP is a serine/threonine kinase receptor associated protein, and its activity can be inhibited by this compound due to its ability to block kinase activity that p49/STRAP may interact with. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR (mammalian target of rapamycin) kinase activity. Since mTOR signaling can regulate serine/threonine kinase activities, the inhibition of mTOR can indirectly reduce the functional activity of p49/STRAP by modulating the downstream kinase signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, this compound disrupts the PI3K/AKT/mTOR pathway, which can indirectly lead to decreased activity of p49/STRAP by altering the phosphorylation states of proteins within this kinase signaling network. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Blocking MEK1/2 activity can lead to the inhibition of ERK signaling, a pathway that may cross-talk with serine/threonine kinase pathways that p49/STRAP is associated with. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Specifically inhibits p38 MAPK, which is involved in stress responses. As p49/STRAP is connected to serine/threonine kinase signaling, inhibiting p38 MAPK can interfere with the pathways that p49/STRAP modulates, thereby decreasing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Acts as a potent inhibitor of PI3K, and by doing so, affects the PI3K/AKT signaling cascade. This interference can decrease the phosphorylation and activation of downstream targets, potentially diminishing the activity of associated proteins like p49/STRAP. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which is part of the stress-activated protein kinase pathway. By blocking JNK activity, this compound can indirectly affect the signaling events that p49/STRAP is involved in, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which prevents the activation of MAPK/ERK. This disruption can modulate the activity of proteins within this pathway, potentially leading to a decrease in the functional activity of p49/STRAP due to altered serine/threonine kinase signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
An inhibitor of p38 MAPK, which by suppressing this kinase, can influence the activity of proteins that interact with p38 MAPK or are part of its signaling pathway, including serine/threonine kinase-associated proteins like p49/STRAP. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
A selective inhibitor of mTOR kinase, leading to the inhibition of both mTORC1 and mTORC2 complexes. The inhibition of these complexes can affect the signaling pathways that p49/STRAP is a part of, thus decreasing its activity indirectly. | ||||||